Loading clinical trials...
Loading clinical trials...
A First-in-human, Open-label, Multicenter Phase I/II Study to Evaluate the Safety and Anti-tumor Activity of ANV600 As Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
Conditions
Interventions
ANV600
ANV600 + pembrolizumab (KEYTRUDA®)
Locations
18
United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Institut Bergonie
Bordeaux, France
CEPCM - AP-HM Hopital de la Timone
Marseille, France
Start Date
July 1, 2024
Primary Completion Date
October 1, 2027
Completion Date
February 1, 2028
Last Updated
March 7, 2025
NCT06898450
NCT05720117
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Anaveon AG
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions